$MLTX

$11.93 +$0.12 (1.02%) Close

$MLTX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 85.1M shares outstanding

Who owns MLTX?

By type of holder

Institutions 85.4% Insiders 0.0% Everyone else 14.7%

Concentration Top 10 holders own 120.9%

BVF Inc/il 18.8% · BVF Partners L P/il 18.8%

Institutional ownership

85.4%

+11.2 pts vs last qtr

Institutional holders

169

+22 vs last qtr

Net shares bought

+9.5M

by institutions in Q2 2026

New / sold out

42 / 20

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

T. Rowe Price Investment Management, Inc. NEW +4.3M
Jupiter Topco LLC NEW +3.1M

Biggest sellers in Q2 2026

Janus Henderson Group PLC SOLD OUT −3.5M
Cormorant Asset Management, LP −1.3M

Who is planning to sell?

Notices of proposed sale, last 12 months

$84M

8 notices from 7 people

Shares covered

4.9M

5.77% of the company

Arranged in advance

14%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

BVF Partners L P/il 10% stockholder $63.5M
Reich Kristian Officer 10b5-1 $5.77M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2021–FY2025

−82.1%

−34.95% a year

Each share's claim on the business

+458.5%

grew without buying or selling a share

Spent on buybacks vs paid in stock

$50 vs $36.9M

over 5 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years38% 1–3 years6% Under 1 year57%

Quarterly turnover

25.0%

of institutional shares changed hands

Top 10 managers, median time held

2 quarters

Super Investors

Investment managers reporting MLTX on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
BI BVF Inc/il 13D · 19.7%	16.0M	18.80%	Unchanged	2022	8.0%
Shares held by quarter Peak holding21.8M (Q3'24) Change over 8 quarters−5.8M Share of the company18.800% Disclosed stake13D · 19.7% BVF Inc/il's full portfolio →
DT Deep Track Capital, LP	7.0M	8.22%	+590.2K (+9.2%)	Q4 '25	2.0%
Shares held by quarter Peak holding7.0M (Q2'26) Change over 8 quarters+7.0M Share of the company8.220% Deep Track Capital, LP's full portfolio →

BVF Inc/il

13D · 19.7%

16.0M

% of company

18.80%

Change vs last qtr

Unchanged

Held since

2022

Deep Track Capital, LP

7.0M

% of company

8.22%

Change vs last qtr

+590.2K (+9.2%)

Held since

Q4 '25

28 more super investors behind a free account

See every manager holding MoonLake Immunotherapeutics, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting MLTX on Form N-PORT; together they hold 6.7% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
TR T. Rowe Price Capital Appreciation Fund T. Rowe Price Capital Appreciation Fund, Inc.	$31.4M	1.6M	1.90%	0.04%	June 30, 2026
TR T. Rowe Price Small-Cap Value Fund, Inc. T. Rowe Price Small-Cap Value Fund, Inc.	$17.9M	918.6K	1.08%	0.17%	June 30, 2026

T. Rowe Price Capital Appreciation Fund

T. Rowe Price Capital Appreciation Fund, Inc.

Position value

$31.4M

% of company

1.90%

% of the fund

0.04%

As of

June 30, 2026

T. Rowe Price Small-Cap Value Fund, Inc.

Position value

$17.9M

% of company

1.08%

% of the fund

0.17%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding MoonLake Immunotherapeutics and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
BP BVF Partners L P/il 5%+ holder 13D · 19.7%	16.0M	18.80%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company18.800% Disclosed stake13D · 19.7% View the 13D/G filing →
LM Lampert Mark N 5%+ holder 13D · 19.7%	16.0M	18.80%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company18.800% Disclosed stake13D · 19.7% View the 13D/G filing →

BVF Partners L P/il

5%+ holder13D · 19.7%

16.0M

% of company

18.80%

Change vs last qtr

—

Held since

—

Lampert Mark N

5%+ holder13D · 19.7%

16.0M

% of company

18.80%

Change vs last qtr

—

Held since

—

8 more holders behind a free account

See every insider and 5%+ holder of MoonLake Immunotherapeutics.

Comments